Moreover, CHIP is a marker of poorer prognosis in patients with non-Hodgkin lymphoma and multiple myeloma (MM) receiving autologous stem cell transplantation (ASCT) [10]. The gene discussed is STUB1; the disease is plasma cell myeloma.